Uploads bring prompts and responses, but not project files, attachments, or AI-generated images. The rollout skips the UK, ...
Active exploits, nation-state campaigns, fresh arrests, and critical CVEs — this week's cybersecurity recap has it all.
Cerevance has said it plans to move on to late-stage trials of its first-in-class Parkinson's disease drug CVN424 after hitting the mark in a phase 2 proof-of-concept study. The Boston-based biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results